BIO-PATH HOLDINGS INC (BPTH)
US09057N4097 - Common Stock
Overall BPTH gets a fundamental rating of 0 out of 10. We evaluated BPTH against 568 industry peers in the Biotechnology industry. BPTH may be in some trouble as it scores bad on both profitability and health. BPTH has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year BPTH has reported negative net income.
BPTH had a negative operating cash flow in the past year.
BPTH had negative earnings in each of the past 5 years.
In the past 5 years BPTH always reported negative operating cash flow.
1.2 Ratios
BPTH's Return On Assets of -354.57% is on the low side compared to the rest of the industry. BPTH is outperformed by 96.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -354.57% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-208.48%
ROA(5y)-145.89%
ROE(3y)-1261.55%
ROE(5y)-779.53%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for BPTH so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BPTH has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BPTH has more shares outstanding
There is no outstanding debt for BPTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -67.13, we must say that BPTH is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BPTH (-67.13) is worse than 95.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -67.13 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
BPTH has a Current Ratio of 0.86. This is a bad value and indicates that BPTH is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of BPTH (0.86) is worse than 89.20% of its industry peers.
A Quick Ratio of 0.86 indicates that BPTH may have some problems paying its short term obligations.
BPTH has a worse Quick ratio (0.86) than 88.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.86 | ||
| Quick Ratio | 0.86 |
3. Growth
3.1 Past
BPTH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.03%, which is quite impressive.
EPS 1Y (TTM)66.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.06%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 15.40% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y91.32%
EPS Next 2Y39.91%
EPS Next 3Y23.7%
EPS Next 5Y15.4%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BPTH. In the last year negative earnings were reported.
Also next year BPTH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BPTH's earnings are expected to grow with 23.70% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.91%
EPS Next 3Y23.7%
5. Dividend
5.1 Amount
No dividends for BPTH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIO-PATH HOLDINGS INC
NASDAQ:BPTH (12/19/2024, 8:20:26 PM)
Premarket: 1.15 -0.34 (-22.82%)1.49
+0.82 (+122.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1.7%
Inst Owner Change-48.66%
Ins Owners6.71%
Ins Owner Change0%
Market Cap6.42M
Analysts82.86
Price Target12.24 (721.48%)
Short Float %0.72%
Short Ratio0.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.44%
Min EPS beat(2)26.15%
Max EPS beat(2)32.72%
EPS beat(4)2
Avg EPS beat(4)6.37%
Min EPS beat(4)-28%
Max EPS beat(4)32.72%
EPS beat(8)4
Avg EPS beat(8)-2.97%
EPS beat(12)5
Avg EPS beat(12)-7.88%
EPS beat(16)9
Avg EPS beat(16)-0.13%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-40%
PT rev (3m)-40%
EPS NQ rev (1m)92.37%
EPS NQ rev (3m)92.37%
EPS NY rev (1m)48.87%
EPS NY rev (3m)48.87%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-13.79
EYN/A
EPS(NY)-1.58
Fwd EYN/A
FCF(TTM)-2.21
FCFYN/A
OCF(TTM)-2.21
OCFYN/A
SpS0
BVpS-0.17
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -354.57% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-208.48%
ROA(5y)-145.89%
ROE(3y)-1261.55%
ROE(5y)-779.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.86 | ||
| Quick Ratio | 0.86 | ||
| Altman-Z | -67.13 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.06%
EPS Next Y91.32%
EPS Next 2Y39.91%
EPS Next 3Y23.7%
EPS Next 5Y15.4%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y26.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.32%
OCF growth 3YN/A
OCF growth 5YN/A